nodes	percent_of_prediction	percent_of_DWPC	metapath
Fludarabine—RRM1—larynx—thyroid cancer	0.0657	0.36	CbGeAlD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—CCDC6—thyroid cancer	0.0276	0.144	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—CCDC6—thyroid cancer	0.0212	0.111	CbGpPWpGaD
Fludarabine—SLC28A3—trachea—thyroid cancer	0.0188	0.103	CbGeAlD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—CCDC6—thyroid cancer	0.0155	0.081	CbGpPWpGaD
Fludarabine—DCK—saliva-secreting gland—thyroid cancer	0.0105	0.0578	CbGeAlD
Fludarabine—POLA1—thyroid gland—thyroid cancer	0.0104	0.0572	CbGeAlD
Fludarabine—RRM1—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.00892	0.0465	CbGpPWpGaD
Fludarabine—SLC29A1—trachea—thyroid cancer	0.00852	0.0467	CbGeAlD
Fludarabine—RRM1—thyroid gland—thyroid cancer	0.00829	0.0454	CbGeAlD
Fludarabine—POLA1—G1/S-Specific Transcription—CDK1—thyroid cancer	0.00827	0.0431	CbGpPWpGaD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.00816	0.0425	CbGpPWpGaD
Fludarabine—DCK—trachea—thyroid cancer	0.00814	0.0446	CbGeAlD
Fludarabine—RRM1—head—thyroid cancer	0.00735	0.0403	CbGeAlD
Fludarabine—SLC29A1—thyroid gland—thyroid cancer	0.00674	0.0369	CbGeAlD
Fludarabine—POLA1—lymph node—thyroid cancer	0.00648	0.0356	CbGeAlD
Fludarabine—DCK—thyroid gland—thyroid cancer	0.00644	0.0353	CbGeAlD
Fludarabine—DCK—Doxorubicin—Epirubicin—thyroid cancer	0.00641	0.519	CbGdCrCtD
Fludarabine—SLC29A1—head—thyroid cancer	0.00598	0.0328	CbGeAlD
Fludarabine—DCK—Epirubicin—Doxorubicin—thyroid cancer	0.00593	0.481	CbGdCrCtD
Fludarabine—DCK—head—thyroid cancer	0.00571	0.0313	CbGeAlD
Fludarabine—RRM1—lymph node—thyroid cancer	0.00515	0.0282	CbGeAlD
Fludarabine—POLA1—E2F mediated regulation of DNA replication—CDK1—thyroid cancer	0.00486	0.0253	CbGpPWpGaD
Fludarabine—RRM1—E2F transcription factor network—CDK1—thyroid cancer	0.00457	0.0238	CbGpPWpGaD
Fludarabine—SLC29A1—lymph node—thyroid cancer	0.00419	0.0229	CbGeAlD
Fludarabine—DCK—lymph node—thyroid cancer	0.004	0.0219	CbGeAlD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—CDK1—thyroid cancer	0.00398	0.0207	CbGpPWpGaD
Fludarabine—POLA1—Extension of Telomeres—TERT—thyroid cancer	0.00389	0.0202	CbGpPWpGaD
Fludarabine—Adenosine triphosphate—AKT1—thyroid cancer	0.00372	1	CrCbGaD
Fludarabine—Visual impairment—Vandetanib—thyroid cancer	0.00325	0.00533	CcSEcCtD
Fludarabine—Erythema multiforme—Vandetanib—thyroid cancer	0.00319	0.00523	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—CDK1—thyroid cancer	0.00306	0.0159	CbGpPWpGaD
Fludarabine—Dehydration—Sorafenib—thyroid cancer	0.00306	0.00502	CcSEcCtD
Fludarabine—Mucosal inflammation—Epirubicin—thyroid cancer	0.00302	0.00496	CcSEcCtD
Fludarabine—Blindness—Epirubicin—thyroid cancer	0.00302	0.00496	CcSEcCtD
Fludarabine—Arrhythmia—Vandetanib—thyroid cancer	0.00301	0.00494	CcSEcCtD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.003	0.0156	CbGpPWpGaD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—CP—thyroid cancer	0.003	0.0156	CbGpPWpGaD
Fludarabine—Alopecia—Vandetanib—thyroid cancer	0.00298	0.00489	CcSEcCtD
Fludarabine—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.00296	0.00486	CcSEcCtD
Fludarabine—Malnutrition—Vandetanib—thyroid cancer	0.00294	0.00481	CcSEcCtD
Fludarabine—Dysphagia—Sorafenib—thyroid cancer	0.00284	0.00466	CcSEcCtD
Fludarabine—Mucosal inflammation—Doxorubicin—thyroid cancer	0.0028	0.00459	CcSEcCtD
Fludarabine—Blindness—Doxorubicin—thyroid cancer	0.0028	0.00459	CcSEcCtD
Fludarabine—Optic neuritis—Epirubicin—thyroid cancer	0.00272	0.00446	CcSEcCtD
Fludarabine—Neutropenia—Sorafenib—thyroid cancer	0.00266	0.00436	CcSEcCtD
Fludarabine—POLA1—E2F transcription factor network—CDK1—thyroid cancer	0.00258	0.0134	CbGpPWpGaD
Fludarabine—Cough—Vandetanib—thyroid cancer	0.00256	0.0042	CcSEcCtD
Fludarabine—Pneumonia—Sorafenib—thyroid cancer	0.00255	0.00418	CcSEcCtD
Fludarabine—Convulsion—Vandetanib—thyroid cancer	0.00254	0.00417	CcSEcCtD
Fludarabine—Optic neuritis—Doxorubicin—thyroid cancer	0.00252	0.00413	CcSEcCtD
Fludarabine—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00251	0.00412	CcSEcCtD
Fludarabine—Arthralgia—Vandetanib—thyroid cancer	0.0025	0.0041	CcSEcCtD
Fludarabine—Acute coronary syndrome—Sorafenib—thyroid cancer	0.0025	0.0041	CcSEcCtD
Fludarabine—Renal failure—Sorafenib—thyroid cancer	0.00249	0.00409	CcSEcCtD
Fludarabine—Myocardial infarction—Sorafenib—thyroid cancer	0.00248	0.00407	CcSEcCtD
Fludarabine—Neuropathy peripheral—Sorafenib—thyroid cancer	0.00248	0.00407	CcSEcCtD
Fludarabine—Bone marrow depression—Epirubicin—thyroid cancer	0.00248	0.00407	CcSEcCtD
Fludarabine—Stomatitis—Sorafenib—thyroid cancer	0.00247	0.00405	CcSEcCtD
Fludarabine—Seborrhoeic dermatitis—Epirubicin—thyroid cancer	0.00246	0.00403	CcSEcCtD
Fludarabine—Oedema—Vandetanib—thyroid cancer	0.0024	0.00393	CcSEcCtD
Fludarabine—Epistaxis—Sorafenib—thyroid cancer	0.00239	0.00392	CcSEcCtD
Fludarabine—Infection—Vandetanib—thyroid cancer	0.00238	0.0039	CcSEcCtD
Fludarabine—RRM1—Fluoropyrimidine Activity—TP53—thyroid cancer	0.00237	0.0123	CbGpPWpGaD
Fludarabine—Nervous system disorder—Vandetanib—thyroid cancer	0.00235	0.00385	CcSEcCtD
Fludarabine—Thrombocytopenia—Vandetanib—thyroid cancer	0.00235	0.00385	CcSEcCtD
Fludarabine—Bone marrow depression—Doxorubicin—thyroid cancer	0.00229	0.00376	CcSEcCtD
Fludarabine—Haemoglobin—Sorafenib—thyroid cancer	0.00229	0.00375	CcSEcCtD
Fludarabine—Haemorrhage—Sorafenib—thyroid cancer	0.00227	0.00373	CcSEcCtD
Fludarabine—Seborrhoeic dermatitis—Doxorubicin—thyroid cancer	0.00227	0.00373	CcSEcCtD
Fludarabine—Haemoptysis—Epirubicin—thyroid cancer	0.00226	0.00371	CcSEcCtD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.00224	0.0117	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—CDK1—thyroid cancer	0.00224	0.0117	CbGpPWpGaD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00223	0.0116	CbGpPWpGaD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00223	0.0116	CbGpPWpGaD
Fludarabine—Herpes zoster—Epirubicin—thyroid cancer	0.00222	0.00365	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00218	0.00358	CcSEcCtD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—TP53—thyroid cancer	0.00217	0.0113	CbGpPWpGaD
Fludarabine—Paraesthesia—Vandetanib—thyroid cancer	0.00215	0.00353	CcSEcCtD
Fludarabine—Erythema multiforme—Sorafenib—thyroid cancer	0.00215	0.00353	CcSEcCtD
Fludarabine—Dyspnoea—Vandetanib—thyroid cancer	0.00214	0.0035	CcSEcCtD
Fludarabine—Dyspepsia—Vandetanib—thyroid cancer	0.00211	0.00346	CcSEcCtD
Fludarabine—Haemoptysis—Doxorubicin—thyroid cancer	0.00209	0.00343	CcSEcCtD
Fludarabine—Decreased appetite—Vandetanib—thyroid cancer	0.00208	0.00342	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00207	0.00339	CcSEcCtD
Fludarabine—Fatigue—Vandetanib—thyroid cancer	0.00207	0.00339	CcSEcCtD
Fludarabine—Herpes zoster—Doxorubicin—thyroid cancer	0.00206	0.00337	CcSEcCtD
Fludarabine—Pain—Vandetanib—thyroid cancer	0.00205	0.00336	CcSEcCtD
Fludarabine—Constipation—Vandetanib—thyroid cancer	0.00205	0.00336	CcSEcCtD
Fludarabine—Arrhythmia—Sorafenib—thyroid cancer	0.00203	0.00333	CcSEcCtD
Fludarabine—Alopecia—Sorafenib—thyroid cancer	0.00201	0.0033	CcSEcCtD
Fludarabine—Malnutrition—Sorafenib—thyroid cancer	0.00198	0.00325	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.00197	0.0102	CbGpPWpGaD
Fludarabine—Body temperature increased—Vandetanib—thyroid cancer	0.00189	0.00311	CcSEcCtD
Fludarabine—POLA1—G1/S Transition—CDK1—thyroid cancer	0.00187	0.00974	CbGpPWpGaD
Fludarabine—Anaemia—Sorafenib—thyroid cancer	0.00183	0.003	CcSEcCtD
Fludarabine—Hypocalcaemia—Epirubicin—thyroid cancer	0.00183	0.003	CcSEcCtD
Fludarabine—Hyperuricaemia—Epirubicin—thyroid cancer	0.0018	0.00296	CcSEcCtD
Fludarabine—Leukopenia—Sorafenib—thyroid cancer	0.00177	0.00291	CcSEcCtD
Fludarabine—POLA1—Telomere Maintenance—TERT—thyroid cancer	0.00176	0.00918	CbGpPWpGaD
Fludarabine—Cough—Sorafenib—thyroid cancer	0.00173	0.00283	CcSEcCtD
Fludarabine—Asthenia—Vandetanib—thyroid cancer	0.00172	0.00282	CcSEcCtD
Fludarabine—Blood uric acid increased—Epirubicin—thyroid cancer	0.0017	0.0028	CcSEcCtD
Fludarabine—Pruritus—Vandetanib—thyroid cancer	0.00169	0.00278	CcSEcCtD
Fludarabine—Hypocalcaemia—Doxorubicin—thyroid cancer	0.00169	0.00278	CcSEcCtD
Fludarabine—Arthralgia—Sorafenib—thyroid cancer	0.00169	0.00277	CcSEcCtD
Fludarabine—Myalgia—Sorafenib—thyroid cancer	0.00169	0.00277	CcSEcCtD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.00167	0.00872	CbGpPWpGaD
Fludarabine—Hyperuricaemia—Doxorubicin—thyroid cancer	0.00167	0.00274	CcSEcCtD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.00166	0.00863	CbGpPWpGaD
Fludarabine—Hyperkalaemia—Epirubicin—thyroid cancer	0.00164	0.0027	CcSEcCtD
Fludarabine—Diarrhoea—Vandetanib—thyroid cancer	0.00164	0.00269	CcSEcCtD
Fludarabine—Anaphylactic shock—Sorafenib—thyroid cancer	0.00162	0.00265	CcSEcCtD
Fludarabine—Infection—Sorafenib—thyroid cancer	0.00161	0.00263	CcSEcCtD
Fludarabine—Nervous system disorder—Sorafenib—thyroid cancer	0.00158	0.0026	CcSEcCtD
Fludarabine—Thrombocytopenia—Sorafenib—thyroid cancer	0.00158	0.0026	CcSEcCtD
Fludarabine—Blood uric acid increased—Doxorubicin—thyroid cancer	0.00158	0.00259	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CDK1—thyroid cancer	0.00158	0.00821	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—MINPP1—thyroid cancer	0.00157	0.00819	CbGpPWpGaD
Fludarabine—Anorexia—Sorafenib—thyroid cancer	0.00154	0.00253	CcSEcCtD
Fludarabine—Oesophagitis—Epirubicin—thyroid cancer	0.00153	0.00251	CcSEcCtD
Fludarabine—Coma—Epirubicin—thyroid cancer	0.00153	0.00251	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00152	0.00794	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—CP—thyroid cancer	0.00152	0.00794	CbGpPWpGaD
Fludarabine—Vomiting—Vandetanib—thyroid cancer	0.00152	0.0025	CcSEcCtD
Fludarabine—Hyperkalaemia—Doxorubicin—thyroid cancer	0.00152	0.0025	CcSEcCtD
Fludarabine—Rash—Vandetanib—thyroid cancer	0.00151	0.00248	CcSEcCtD
Fludarabine—Dermatitis—Vandetanib—thyroid cancer	0.00151	0.00248	CcSEcCtD
Fludarabine—Headache—Vandetanib—thyroid cancer	0.0015	0.00246	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.0015	0.00781	CbGpPWpGaD
Fludarabine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00147	0.00241	CcSEcCtD
Fludarabine—POLA1—Chromosome Maintenance—TERT—thyroid cancer	0.00147	0.00764	CbGpPWpGaD
Fludarabine—Dyspnoea—Sorafenib—thyroid cancer	0.00144	0.00236	CcSEcCtD
Fludarabine—Nausea—Vandetanib—thyroid cancer	0.00142	0.00233	CcSEcCtD
Fludarabine—Dyspepsia—Sorafenib—thyroid cancer	0.00142	0.00233	CcSEcCtD
Fludarabine—Coma—Doxorubicin—thyroid cancer	0.00142	0.00232	CcSEcCtD
Fludarabine—Oesophagitis—Doxorubicin—thyroid cancer	0.00142	0.00232	CcSEcCtD
Fludarabine—Phlebitis—Epirubicin—thyroid cancer	0.00141	0.00231	CcSEcCtD
Fludarabine—Decreased appetite—Sorafenib—thyroid cancer	0.0014	0.0023	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—PCM1—thyroid cancer	0.0014	0.00727	CbGpPWpGaD
Fludarabine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.0014	0.00229	CcSEcCtD
Fludarabine—Fatigue—Sorafenib—thyroid cancer	0.00139	0.00229	CcSEcCtD
Fludarabine—Pain—Sorafenib—thyroid cancer	0.00138	0.00227	CcSEcCtD
Fludarabine—Constipation—Sorafenib—thyroid cancer	0.00138	0.00227	CcSEcCtD
Fludarabine—Hepatic failure—Epirubicin—thyroid cancer	0.00135	0.00222	CcSEcCtD
Fludarabine—Cardiac failure congestive—Epirubicin—thyroid cancer	0.00134	0.0022	CcSEcCtD
Fludarabine—RRM1—Metabolism—NDUFA13—thyroid cancer	0.00134	0.00696	CbGpPWpGaD
Fludarabine—Phlebitis—Doxorubicin—thyroid cancer	0.0013	0.00214	CcSEcCtD
Fludarabine—Body temperature increased—Sorafenib—thyroid cancer	0.00128	0.0021	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.00127	0.00664	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CHST14—thyroid cancer	0.00126	0.00655	CbGpPWpGaD
Fludarabine—Hepatic failure—Doxorubicin—thyroid cancer	0.00125	0.00205	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—PCM1—thyroid cancer	0.00125	0.0065	CbGpPWpGaD
Fludarabine—Cardiac failure—Epirubicin—thyroid cancer	0.00125	0.00204	CcSEcCtD
Fludarabine—Cerebrovascular accident—Epirubicin—thyroid cancer	0.00124	0.00203	CcSEcCtD
Fludarabine—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.00124	0.00203	CcSEcCtD
Fludarabine—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.00122	0.00199	CcSEcCtD
Fludarabine—DCK—Metabolism—MINPP1—thyroid cancer	0.00121	0.0063	CbGpPWpGaD
Fludarabine—Hypersensitivity—Sorafenib—thyroid cancer	0.00119	0.00195	CcSEcCtD
Fludarabine—Asthenia—Sorafenib—thyroid cancer	0.00116	0.0019	CcSEcCtD
Fludarabine—Cardiac failure—Doxorubicin—thyroid cancer	0.00115	0.00189	CcSEcCtD
Fludarabine—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.00115	0.00188	CcSEcCtD
Fludarabine—Pruritus—Sorafenib—thyroid cancer	0.00114	0.00188	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00114	0.00594	CbGpPWpGaD
Fludarabine—POLA1—Mitotic M-M/G1 phases—TPR—thyroid cancer	0.00114	0.00594	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—CP—thyroid cancer	0.00114	0.00592	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00114	0.00592	CbGpPWpGaD
Fludarabine—Dehydration—Epirubicin—thyroid cancer	0.00113	0.00185	CcSEcCtD
Fludarabine—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.00112	0.00184	CcSEcCtD
Fludarabine—Liver function test abnormal—Epirubicin—thyroid cancer	0.00112	0.00184	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00112	0.00582	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.00111	0.00577	CbGpPWpGaD
Fludarabine—Diarrhoea—Sorafenib—thyroid cancer	0.00111	0.00181	CcSEcCtD
Fludarabine—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.00109	0.00179	CcSEcCtD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	0.00109	0.00568	CbGpPWpGaD
Fludarabine—Dysphagia—Epirubicin—thyroid cancer	0.00105	0.00172	CcSEcCtD
Fludarabine—Dehydration—Doxorubicin—thyroid cancer	0.00105	0.00172	CcSEcCtD
Fludarabine—Liver function test abnormal—Doxorubicin—thyroid cancer	0.00104	0.0017	CcSEcCtD
Fludarabine—DCK—Metabolism—NDUFA13—thyroid cancer	0.00103	0.00536	CbGpPWpGaD
Fludarabine—Vomiting—Sorafenib—thyroid cancer	0.00103	0.00169	CcSEcCtD
Fludarabine—Angina pectoris—Epirubicin—thyroid cancer	0.00102	0.00168	CcSEcCtD
Fludarabine—Rash—Sorafenib—thyroid cancer	0.00102	0.00167	CcSEcCtD
Fludarabine—Dermatitis—Sorafenib—thyroid cancer	0.00102	0.00167	CcSEcCtD
Fludarabine—RRM1—Metabolism—HPGD—thyroid cancer	0.00101	0.00528	CbGpPWpGaD
Fludarabine—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.00101	0.00166	CcSEcCtD
Fludarabine—Headache—Sorafenib—thyroid cancer	0.00101	0.00166	CcSEcCtD
Fludarabine—Bronchitis—Epirubicin—thyroid cancer	0.00101	0.00166	CcSEcCtD
Fludarabine—Pancytopenia—Epirubicin—thyroid cancer	0.000997	0.00164	CcSEcCtD
Fludarabine—Dysuria—Epirubicin—thyroid cancer	0.000982	0.00161	CcSEcCtD
Fludarabine—Neutropenia—Epirubicin—thyroid cancer	0.000982	0.00161	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000977	0.00509	CbGpPWpGaD
Fludarabine—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000976	0.0016	CcSEcCtD
Fludarabine—Dysphagia—Doxorubicin—thyroid cancer	0.000972	0.00159	CcSEcCtD
Fludarabine—DCK—Metabolism—CHST14—thyroid cancer	0.000967	0.00504	CbGpPWpGaD
Fludarabine—Nausea—Sorafenib—thyroid cancer	0.00096	0.00157	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000958	0.00499	CbGpPWpGaD
Fludarabine—Hyperglycaemia—Epirubicin—thyroid cancer	0.000947	0.00155	CcSEcCtD
Fludarabine—Angina pectoris—Doxorubicin—thyroid cancer	0.000947	0.00155	CcSEcCtD
Fludarabine—Pneumonia—Epirubicin—thyroid cancer	0.000942	0.00154	CcSEcCtD
Fludarabine—Bronchitis—Doxorubicin—thyroid cancer	0.000934	0.00153	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—thyroid cancer	0.000933	0.00486	CbGpPWpGaD
Fludarabine—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000928	0.00152	CcSEcCtD
Fludarabine—Pancytopenia—Doxorubicin—thyroid cancer	0.000923	0.00151	CcSEcCtD
Fludarabine—Renal failure—Epirubicin—thyroid cancer	0.00092	0.00151	CcSEcCtD
Fludarabine—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000918	0.00151	CcSEcCtD
Fludarabine—Stomatitis—Epirubicin—thyroid cancer	0.000913	0.0015	CcSEcCtD
Fludarabine—Urinary tract infection—Epirubicin—thyroid cancer	0.00091	0.00149	CcSEcCtD
Fludarabine—Dysuria—Doxorubicin—thyroid cancer	0.000909	0.00149	CcSEcCtD
Fludarabine—Neutropenia—Doxorubicin—thyroid cancer	0.000909	0.00149	CcSEcCtD
Fludarabine—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000903	0.00148	CcSEcCtD
Fludarabine—Haematuria—Epirubicin—thyroid cancer	0.000893	0.00146	CcSEcCtD
Fludarabine—Epistaxis—Epirubicin—thyroid cancer	0.000883	0.00145	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000883	0.0046	CbGpPWpGaD
Fludarabine—Sinusitis—Epirubicin—thyroid cancer	0.000878	0.00144	CcSEcCtD
Fludarabine—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000877	0.00144	CcSEcCtD
Fludarabine—Pneumonia—Doxorubicin—thyroid cancer	0.000871	0.00143	CcSEcCtD
Fludarabine—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000859	0.00141	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—TPR—thyroid cancer	0.000853	0.00444	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000852	0.00444	CbGpPWpGaD
Fludarabine—Renal failure—Doxorubicin—thyroid cancer	0.000852	0.0014	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00085	0.00443	CbGpPWpGaD
Fludarabine—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000849	0.00139	CcSEcCtD
Fludarabine—Haemoglobin—Epirubicin—thyroid cancer	0.000845	0.00139	CcSEcCtD
Fludarabine—Stomatitis—Doxorubicin—thyroid cancer	0.000845	0.00139	CcSEcCtD
Fludarabine—Urinary tract infection—Doxorubicin—thyroid cancer	0.000842	0.00138	CcSEcCtD
Fludarabine—Haemorrhage—Epirubicin—thyroid cancer	0.000841	0.00138	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	0.000839	0.00437	CbGpPWpGaD
Fludarabine—Hypoaesthesia—Epirubicin—thyroid cancer	0.000836	0.00137	CcSEcCtD
Fludarabine—Pharyngitis—Epirubicin—thyroid cancer	0.000834	0.00137	CcSEcCtD
Fludarabine—Haematuria—Doxorubicin—thyroid cancer	0.000826	0.00136	CcSEcCtD
Fludarabine—Epistaxis—Doxorubicin—thyroid cancer	0.000817	0.00134	CcSEcCtD
Fludarabine—Sinusitis—Doxorubicin—thyroid cancer	0.000813	0.00133	CcSEcCtD
Fludarabine—Visual impairment—Epirubicin—thyroid cancer	0.00081	0.00133	CcSEcCtD
Fludarabine—Erythema multiforme—Epirubicin—thyroid cancer	0.000795	0.0013	CcSEcCtD
Fludarabine—Haemoglobin—Doxorubicin—thyroid cancer	0.000782	0.00128	CcSEcCtD
Fludarabine—DCK—Metabolism—HPGD—thyroid cancer	0.000779	0.00406	CbGpPWpGaD
Fludarabine—Haemorrhage—Doxorubicin—thyroid cancer	0.000778	0.00128	CcSEcCtD
Fludarabine—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000774	0.00127	CcSEcCtD
Fludarabine—POLA1—Mitotic M-M/G1 phases—CDK1—thyroid cancer	0.000773	0.00403	CbGpPWpGaD
Fludarabine—Pharyngitis—Doxorubicin—thyroid cancer	0.000772	0.00127	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—TPR—thyroid cancer	0.000762	0.00397	CbGpPWpGaD
Fludarabine—Chills—Epirubicin—thyroid cancer	0.000754	0.00124	CcSEcCtD
Fludarabine—Arrhythmia—Epirubicin—thyroid cancer	0.000751	0.00123	CcSEcCtD
Fludarabine—Visual impairment—Doxorubicin—thyroid cancer	0.00075	0.00123	CcSEcCtD
Fludarabine—Alopecia—Epirubicin—thyroid cancer	0.000743	0.00122	CcSEcCtD
Fludarabine—Erythema multiforme—Doxorubicin—thyroid cancer	0.000735	0.00121	CcSEcCtD
Fludarabine—Malnutrition—Epirubicin—thyroid cancer	0.000732	0.0012	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000714	0.00372	CbGpPWpGaD
Fludarabine—POLA1—S Phase—CCND1—thyroid cancer	0.000707	0.00368	CbGpPWpGaD
Fludarabine—Chills—Doxorubicin—thyroid cancer	0.000698	0.00114	CcSEcCtD
Fludarabine—Arrhythmia—Doxorubicin—thyroid cancer	0.000695	0.00114	CcSEcCtD
Fludarabine—Alopecia—Doxorubicin—thyroid cancer	0.000687	0.00113	CcSEcCtD
Fludarabine—Ill-defined disorder—Epirubicin—thyroid cancer	0.000679	0.00111	CcSEcCtD
Fludarabine—Malnutrition—Doxorubicin—thyroid cancer	0.000677	0.00111	CcSEcCtD
Fludarabine—Anaemia—Epirubicin—thyroid cancer	0.000676	0.00111	CcSEcCtD
Fludarabine—Agitation—Epirubicin—thyroid cancer	0.000672	0.0011	CcSEcCtD
Fludarabine—Malaise—Epirubicin—thyroid cancer	0.00066	0.00108	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CCND1—thyroid cancer	0.000656	0.00342	CbGpPWpGaD
Fludarabine—Leukopenia—Epirubicin—thyroid cancer	0.000655	0.00107	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000654	0.00341	CbGpPWpGaD
Fludarabine—Cough—Epirubicin—thyroid cancer	0.000639	0.00105	CcSEcCtD
Fludarabine—Convulsion—Epirubicin—thyroid cancer	0.000634	0.00104	CcSEcCtD
Fludarabine—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000628	0.00103	CcSEcCtD
Fludarabine—Anaemia—Doxorubicin—thyroid cancer	0.000626	0.00103	CcSEcCtD
Fludarabine—Myalgia—Epirubicin—thyroid cancer	0.000623	0.00102	CcSEcCtD
Fludarabine—Arthralgia—Epirubicin—thyroid cancer	0.000623	0.00102	CcSEcCtD
Fludarabine—Agitation—Doxorubicin—thyroid cancer	0.000622	0.00102	CcSEcCtD
Fludarabine—Discomfort—Epirubicin—thyroid cancer	0.000615	0.00101	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—thyroid cancer	0.000614	0.0032	CbGpPWpGaD
Fludarabine—Malaise—Doxorubicin—thyroid cancer	0.000611	0.001	CcSEcCtD
Fludarabine—Leukopenia—Doxorubicin—thyroid cancer	0.000606	0.000994	CcSEcCtD
Fludarabine—Confusional state—Epirubicin—thyroid cancer	0.000602	0.000988	CcSEcCtD
Fludarabine—Oedema—Epirubicin—thyroid cancer	0.000597	0.00098	CcSEcCtD
Fludarabine—Anaphylactic shock—Epirubicin—thyroid cancer	0.000597	0.00098	CcSEcCtD
Fludarabine—Infection—Epirubicin—thyroid cancer	0.000593	0.000973	CcSEcCtD
Fludarabine—Cough—Doxorubicin—thyroid cancer	0.000591	0.000969	CcSEcCtD
Fludarabine—Convulsion—Doxorubicin—thyroid cancer	0.000587	0.000962	CcSEcCtD
Fludarabine—Nervous system disorder—Epirubicin—thyroid cancer	0.000586	0.000961	CcSEcCtD
Fludarabine—Thrombocytopenia—Epirubicin—thyroid cancer	0.000585	0.000959	CcSEcCtD
Fludarabine—RRM1—Metabolism—TPR—thyroid cancer	0.000582	0.00303	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000581	0.00303	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—CDK1—thyroid cancer	0.000578	0.00301	CbGpPWpGaD
Fludarabine—Hyperhidrosis—Epirubicin—thyroid cancer	0.000577	0.000947	CcSEcCtD
Fludarabine—Arthralgia—Doxorubicin—thyroid cancer	0.000576	0.000946	CcSEcCtD
Fludarabine—Myalgia—Doxorubicin—thyroid cancer	0.000576	0.000946	CcSEcCtD
Fludarabine—RRM1—Metabolism—PRKAR1A—thyroid cancer	0.000572	0.00298	CbGpPWpGaD
Fludarabine—Discomfort—Doxorubicin—thyroid cancer	0.00057	0.000934	CcSEcCtD
Fludarabine—Anorexia—Epirubicin—thyroid cancer	0.000569	0.000934	CcSEcCtD
Fludarabine—Confusional state—Doxorubicin—thyroid cancer	0.000557	0.000914	CcSEcCtD
Fludarabine—Oedema—Doxorubicin—thyroid cancer	0.000553	0.000906	CcSEcCtD
Fludarabine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000553	0.000906	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.00055	0.00287	CbGpPWpGaD
Fludarabine—Infection—Doxorubicin—thyroid cancer	0.000549	0.0009	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000544	0.000892	CcSEcCtD
Fludarabine—Nervous system disorder—Doxorubicin—thyroid cancer	0.000542	0.000889	CcSEcCtD
Fludarabine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000541	0.000887	CcSEcCtD
Fludarabine—Paraesthesia—Epirubicin—thyroid cancer	0.000536	0.00088	CcSEcCtD
Fludarabine—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000534	0.000876	CcSEcCtD
Fludarabine—Dyspnoea—Epirubicin—thyroid cancer	0.000532	0.000873	CcSEcCtD
Fludarabine—Anorexia—Doxorubicin—thyroid cancer	0.000527	0.000864	CcSEcCtD
Fludarabine—Dyspepsia—Epirubicin—thyroid cancer	0.000526	0.000862	CcSEcCtD
Fludarabine—Decreased appetite—Epirubicin—thyroid cancer	0.000519	0.000852	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—CDK1—thyroid cancer	0.000517	0.00269	CbGpPWpGaD
Fludarabine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000516	0.000846	CcSEcCtD
Fludarabine—Fatigue—Epirubicin—thyroid cancer	0.000515	0.000845	CcSEcCtD
Fludarabine—Pain—Epirubicin—thyroid cancer	0.000511	0.000838	CcSEcCtD
Fludarabine—Constipation—Epirubicin—thyroid cancer	0.000511	0.000838	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000503	0.000826	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000497	0.00259	CbGpPWpGaD
Fludarabine—Paraesthesia—Doxorubicin—thyroid cancer	0.000496	0.000814	CcSEcCtD
Fludarabine—Dyspnoea—Doxorubicin—thyroid cancer	0.000493	0.000808	CcSEcCtD
Fludarabine—Feeling abnormal—Epirubicin—thyroid cancer	0.000492	0.000807	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	0.000491	0.00256	CbGpPWpGaD
Fludarabine—Dyspepsia—Doxorubicin—thyroid cancer	0.000486	0.000798	CcSEcCtD
Fludarabine—Decreased appetite—Doxorubicin—thyroid cancer	0.00048	0.000788	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.00048	0.0025	CbGpPWpGaD
Fludarabine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000477	0.000783	CcSEcCtD
Fludarabine—Fatigue—Doxorubicin—thyroid cancer	0.000476	0.000781	CcSEcCtD
Fludarabine—Constipation—Doxorubicin—thyroid cancer	0.000473	0.000775	CcSEcCtD
Fludarabine—Pain—Doxorubicin—thyroid cancer	0.000473	0.000775	CcSEcCtD
Fludarabine—Body temperature increased—Epirubicin—thyroid cancer	0.000472	0.000774	CcSEcCtD
Fludarabine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000455	0.000747	CcSEcCtD
Fludarabine—DCK—Metabolism—TPR—thyroid cancer	0.000448	0.00233	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PRKAR1A—thyroid cancer	0.00044	0.00229	CbGpPWpGaD
Fludarabine—Hypersensitivity—Epirubicin—thyroid cancer	0.00044	0.000722	CcSEcCtD
Fludarabine—Body temperature increased—Doxorubicin—thyroid cancer	0.000437	0.000717	CcSEcCtD
Fludarabine—RRM1—Metabolism—SLC5A5—thyroid cancer	0.000435	0.00227	CbGpPWpGaD
Fludarabine—Asthenia—Epirubicin—thyroid cancer	0.000428	0.000703	CcSEcCtD
Fludarabine—Pruritus—Epirubicin—thyroid cancer	0.000423	0.000693	CcSEcCtD
Fludarabine—Diarrhoea—Epirubicin—thyroid cancer	0.000409	0.00067	CcSEcCtD
Fludarabine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000407	0.000668	CcSEcCtD
Fludarabine—Asthenia—Doxorubicin—thyroid cancer	0.000396	0.00065	CcSEcCtD
Fludarabine—Pruritus—Doxorubicin—thyroid cancer	0.000391	0.000641	CcSEcCtD
Fludarabine—Vomiting—Epirubicin—thyroid cancer	0.00038	0.000623	CcSEcCtD
Fludarabine—Diarrhoea—Doxorubicin—thyroid cancer	0.000378	0.00062	CcSEcCtD
Fludarabine—Rash—Epirubicin—thyroid cancer	0.000377	0.000618	CcSEcCtD
Fludarabine—Dermatitis—Epirubicin—thyroid cancer	0.000376	0.000617	CcSEcCtD
Fludarabine—Headache—Epirubicin—thyroid cancer	0.000374	0.000614	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—TERT—thyroid cancer	0.000372	0.00194	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000368	0.00192	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—RXRA—thyroid cancer	0.000366	0.00191	CbGpPWpGaD
Fludarabine—Nausea—Epirubicin—thyroid cancer	0.000355	0.000582	CcSEcCtD
Fludarabine—Vomiting—Doxorubicin—thyroid cancer	0.000351	0.000576	CcSEcCtD
Fludarabine—Rash—Doxorubicin—thyroid cancer	0.000348	0.000571	CcSEcCtD
Fludarabine—Dermatitis—Doxorubicin—thyroid cancer	0.000348	0.000571	CcSEcCtD
Fludarabine—Headache—Doxorubicin—thyroid cancer	0.000346	0.000568	CcSEcCtD
Fludarabine—DCK—Metabolism—SLC5A5—thyroid cancer	0.000335	0.00175	CbGpPWpGaD
Fludarabine—Nausea—Doxorubicin—thyroid cancer	0.000328	0.000538	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000328	0.00171	CbGpPWpGaD
Fludarabine—DCK—Metabolism—RXRA—thyroid cancer	0.000281	0.00147	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	0.000277	0.00144	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—CCND1—thyroid cancer	0.000241	0.00125	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PPARG—thyroid cancer	0.000231	0.0012	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—CCND1—thyroid cancer	0.000215	0.00112	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PTGS2—thyroid cancer	0.000182	0.000947	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PPARG—thyroid cancer	0.000178	0.000926	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PTEN—thyroid cancer	0.000158	0.000826	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—TP53—thyroid cancer	0.000142	0.000739	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PTGS2—thyroid cancer	0.00014	0.000729	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PTEN—thyroid cancer	0.000122	0.000635	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—AKT1—thyroid cancer	9.13e-05	0.000476	CbGpPWpGaD
Fludarabine—DCK—Metabolism—AKT1—thyroid cancer	7.03e-05	0.000366	CbGpPWpGaD
